Pembrolizumab is a monoclonal antibody that binds to programmed cell death protein 1 (PD-1) on T cells, preventing an inactivation signal from programmed death ligand 1 (PD-L1) on tumor cells, thereby enabling T cells to kill tumor cells. The gene discussed is PDCD1; the disease is neoplasm.